Vascular Diseases

Cardiovascular·MeSH: Cardiovascular Diseases

Prevalence

8121.9 / 100K

Incidence

682.0 / 100K/yr

10 drugs in development·6 companies·8 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
Alginic Sodium Diester Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)
cerebroprotein hydroloysate	CHINA PHARMA HOLDINGS, INC. (CPHI)
Cerebroprotein Hydroloysate Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)
CerebroproteinHydroloysate Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)

Phase 3(4)

Drug	Company
[14c]azd0780	ASTRAZENECA PLC (AZN)
[14c]azd0780 solution for infusion	ASTRAZENECA PLC (AZN)
acellular tissue engineered vessel	Humacyte Inc. (HUMA)
Standard Medical Therapy	Merus N.V. (MRUS)

Phase 2(1)

Drug	Company
sln360	Silence Therapeutics Plc (SLN)

Phase 1/Phase 2(1)

Drug	Company
tb-500	IO Biotech, Inc. (IOBT)

BioSniper tracks 10 drugs in development for Vascular Diseases across 6 companies.

There are 8 clinical trials targeting Vascular Diseases tracked by BioSniper.

The estimated prevalence of Vascular Diseases is approximately 8121.9 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.